Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Koru Medical Systems Inc (NQ: KRMD )

2.680 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Koru Medical Systems Inc

< Previous 1 2 3 4 5 Next >
KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference
From KORU Medical Systems
Via Business Wire
Recap: KORU Medical Systems Q4 Earnings
Via Benzinga
Earnings Outlook For KORU Medical Systems
Via Benzinga
KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference
From KORU Medical Systems
Via Business Wire
KORU Medical Systems, Inc Announces Leadership Changes to Support Growth Agenda
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge® Infusion System in Japan
From KORU Medical Systems, Inc.
Via Business Wire
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
From KORU Medical Systems, Inc.
Via Business Wire
KRMD Stock Earnings: KORU Medical Systems Beats EPS, Beats Revenue for Q1 2024
KRMD stock results show that KORU Medical Systems beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
From KORU Medical Systems, Inc.
Via Business Wire
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
Although speculation can be bad for your blood pressure, these compelling penny stocks have some strong endorsements. 
Via InvestorPlace
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
From KORU Medical Systems, Inc.
Via Business Wire
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference
From KORU Medical Systems
Via Business Wire
KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes
From KORU Medical Systems, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.